Some mutant TP53 reactivators have been examined in clinical trials and are employed in the treatment of certain cancer types such as adult acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) with mut-TP53. The gene discussed is TP53; the disease is adult acute myeloid leukemia.